Hormone drug trial aims to shrink dangerous liver fat
NCT ID NCT03375788
Summary
This study tested whether a drug called tesamorelin could reduce liver fat and improve liver health in adults with obesity and nonalcoholic fatty liver disease (NAFLD). Researchers enrolled 51 participants to receive either tesamorelin or a placebo. The goal was to see if boosting a specific growth hormone pathway could help control this common liver condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.